Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a report released on Wednesday,Benzinga reports. They currently have a $118.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 179.18% from the stock’s previous close. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical’s FY2025 earnings at ($4.44) EPS.
Several other brokerages have also recently commented on RARE. Wells Fargo & Company lifted their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. HC Wainwright reissued a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. Piper Sandler upped their target price on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, January 13th. JPMorgan Chase & Co. lowered their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $92.43.
Read Our Latest Analysis on RARE
Ultragenyx Pharmaceutical Price Performance
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping the consensus estimate of ($1.45) by $0.05. The company had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm’s revenue was up 42.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.23) EPS. Analysts expect that Ultragenyx Pharmaceutical will post -6.15 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the transaction, the chief executive officer now directly owns 2,183,985 shares in the company, valued at $92,229,686.55. This represents a 0.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 5.80% of the company’s stock.
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
A number of hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC grew its position in shares of Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after acquiring an additional 294 shares during the last quarter. Motley Fool Asset Management LLC increased its position in Ultragenyx Pharmaceutical by 0.3% during the 3rd quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company’s stock worth $8,005,000 after purchasing an additional 360 shares in the last quarter. KBC Group NV grew its holdings in Ultragenyx Pharmaceutical by 24.5% in the 3rd quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 506 shares during the period. M&T Bank Corp grew its holdings in Ultragenyx Pharmaceutical by 8.1% in the 3rd quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company’s stock valued at $388,000 after buying an additional 525 shares during the period. Finally, Amalgamated Bank grew its holdings in Ultragenyx Pharmaceutical by 13.4% in the 2nd quarter. Amalgamated Bank now owns 5,896 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 696 shares during the period. 97.67% of the stock is currently owned by hedge funds and other institutional investors.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
See Also
- Five stocks we like better than Ultragenyx Pharmaceutical
- What Makes a Stock a Good Dividend Stock?
- Oracle Announces Game-Changing News for the AI Industry
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Netflix Adds 19 Million Subscribers, Growth Is Far For Over
- What is the Nikkei 225 index?
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.